Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-10-05
2010-06-01
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000
Reexamination Certificate
active
07727521
ABSTRACT:
This invention relates to a method for prevention or treatment of ischemia reperfusion injury or multi-organ failure in an individual by administering to said individual an effective amount of an interferon beta.
REFERENCES:
patent: 2003/0053985 (2003-03-01), Shachar et al.
patent: 2006/0034801 (2006-02-01), Jalkanen
patent: 2006/0198821 (2006-09-01), Jalkanen
patent: 0 536 520 (1993-04-01), None
patent: 0536520 (1993-04-01), None
patent: WO 98/33517 (1998-08-01), None
patent: WO 01/23006 (2001-04-01), None
patent: 02080953 (2002-10-01), None
patent: WO 02/080953 (2002-10-01), None
patent: 02089828 (2002-11-01), None
patent: 03075944 (2003-09-01), None
patent: 2004084933 (2004-10-01), None
Mahanty S, et al. Pathogenesis of filoviral haemorrhagic fevers. The Lancet. 2004. vol. 4, p. 487-498.
de Groot K, et al. Wegener's granulomatosis: disease course, assement of activity and extent and treatment. Lupus. vol. 7, p. 285-291.
Herrera JL. Management of acute liver failure. Digestive Diseases. 1998. vol. 16(5), p. 274-283.
Kiss J, et al. IFN-b protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 2007. vol. 37, p. 3334-3338.
Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Toxicol. 2001. vol. 41, p. 775-787.
Lasley RD, et al. Protective effects of adenosine in the reversibly injured heart. Ann. Thorac. Surg. 1995, vol. 60, p. 843-846.
Panigrahi M, et al. a-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Research, 1996, vol. 717, p. 184-188.
Poggetti, R.S. et al. Liver injury is a reversible neutrophil-mediated event following gut ischemia. Arch. Surg., 1992, vol. 127, p. 175-179.
Veldhuis, W. et al., “Interferon-Beta Blocks Infiltration of Inflammatory Cells and Reduces Infarct Volume After Ischemic Stroke in the Rat,” Journal of Cerebral Blood Flow & Metabolism, vol. 23, pp. 1029-1039, 2003 The International Society for Cerebral Blood Flow and Metabolism.
Veldhuis, W. et al., “Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood-Brain Barrier Disruption,” Journal of Cerebral Blood Flow & Metabolism, vol. 23, pp. 1060-1069, 2003 The International Society for Cerebral Blood Flow and Metabolism.
Liu, H. et al., “Interferon-B Administration Confers a Beneficial Outcome in a Rabbit Model of Thromboembolic Cerebral Ischemia,” Neuroscience Letters, vol. 327 (2002), pp. 146-148.
Ferro, J. et al., “Other Neuroprotective Therapies on Trial in Acute Stroke,” Cerebrovascular Diseases 2006, vol. 21 (suppl 2), pp. 127-130.
Maier, C. et al., “Interferon-B Fails to Protect in a Model of Transient Focal Stroke,” Stroke 2006, vol. 37, pp. 1116-1119.
A. O. Shakil, “A Pilot Study of Interferon Alfa and Ribavirin Combination in Liver Transplant Recipients With Recurrent Hepatitis C”, Hepatology, vol. 36, 2002, pp. 1253-1258.
E. Nemoto, et al., “Expression of CD73/ecto-5′-nucleotidase on human gingival fibroblasts and contribution to the inhibition of interleukin-1 α-induced granulocyte-macrophase colony stimulating factor production”, Journal of Periodontal Reseach, vol. 39, 2004, pp. 10-19.
G. Kocić, et al., “Different responses of rat liver adenosine metabolizing enzymes during in vivo and in vitro treatment with interferon-α2b”, Journal of Viral Hepatitis, vol. 5, 1998, pp. 353-356.
H. Liu, et al., “Interferon-β administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia”, Neuroscience Letters, vol. 327, 2002, pp. 146-148.
J. Niemelā, et al., “IFN-α Induced Adenosine Production on the Endothelium: A Mechanism Mediated by CD73 (Ecto-5′Nucleotidase) Up-Regulation”, The Journal of Immunology, vol. 172, 2004, pp. 1646-1653.
K. Kalsi, et al., “Regulation of ecto-5′-nucleotidase by TNF-α in human endothelial cells,” Molecular and Cellular Biochemistry, vol. 232, 2002, pp. 113-119.
L.D. Christensen, “Effects of Immunomodulators on Ecto-5′-Nucleotidase Activity on Blood Mononuclear Cells in Vitro,” Scand. J. Immunol., vol. 35, 1992, pp. 407-413.
J. A. Elias, et al., “Transgenic modeling of interleukin-13 in the lung,”Chest, The Cardiopulmonary and Critical Care Journal, vol. 123, No. 3, Mar. 3, 2003, pp. 339S-345S.
V. Savic, et al., “Induction of ecto-5′-nucleotidase of rat cultured mesangial cells by interleukin-1β and tumour necrosis factor-α”, Immunology 1990, vol. 70, pp. 321-326.
Faron Pharmaceuticals Oy
Hissong Bruce D
Landsman Robert
Rothwell Figg Ernst & Manbeck p.c.
LandOfFree
Method of ameliorating multi-organ failure resulting from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of ameliorating multi-organ failure resulting from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of ameliorating multi-organ failure resulting from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250175